Research Article
Risk Factors for Nonalcoholic Fatty Liver Disease with Different Insulin Resistance in a Nonobese Chinese Population
Table 1
Distributions of study variables among participants with and without nonobese NAFLD.
| | Characteristic | All subjects () | Non-NAFLD () | Nonobese NAFLD () | value | | HOMA-IR>1 () | HOMA-IR ≤1 () | HOMA-IR>1 () | HOMA-IR ≤1 () |
| | Gender | | | | | | 0.075 | | Male, (%) | 877 (69.8%) | 44 (32.6%) | 324 (66.1%) | 69 (27.7%) | 282 (73.6%) | | | Female, (%) | 380 (30.2%) | 91 (67.4%) | 166 (33.9%) | 180 (72.3%) | 101 (26.4%) | | | Age (years), (%) | | | | | | <0.001 | | 18-30 | 326 (25.9%) | 42 (31.1%) | 158 (32.2%) | 57 (22.9%) | 69 (18.0%) | | | 31-40 | 338 (26.9%) | 32 (23.7%) | 111 (22.7%) | 70 (28.1%) | 125 (32.6%) | | | 41-50 | 368 (29.3%) | 32 (23.7%) | 109 (22.2%) | 85 (34.1%) | 142 (37.1%) | | | >50 | 225 (17.9%) | 29 (21.5%) | 112 (22.9%) | 37 (14.9%) | 47 (12.3%) | | | Body mass index (kg/m2), (%) | | | | | | <0.001 | | 18.5-22.9 | 557 (44.3%) | 96 (71.1%) | 303 (61.8%) | 67 (26.9%) | 91 (23.8%) | | | 23.0-24.9 | 700 (55.7%) | 39 (28.9%) | 187 (38.2%) | 182(73.1%) | 292 (76.2%) | | | SBP (mmHg), (%) | | | | | | 0.085 | | ≤117 | 608 (48.4%) | 57 (42.2%) | 244 (49.8%) | 116 (46.6%) | 191 (49.9%) | | | >117 | 649 (51.6%) | 78 (57.8%) | 246 (50.2%) | 133 (53.4%) | 192 (50.1%) | | | DBP (mmHg), (%) | | | | | | 0.972 | | ≤71 | 614 (48.8%) | 60 (44.4%) | 240 (49.0%) | 114 (45.8%) | 200 (52.2%) | | | >71 | 643 (51.2%) | 75 (55.6%) | 250 (51.0%) | 135 (54.2%) | 183 (47.8%) | | | Alanine aminotransferase (U/L), (%) | | | | | | <0.001 | | ≤17 | 448 (35.6%) | 68 (50.4%) | 253(51.6%) | 49 (19.4%) | 78 (20.4%) | | | >17 | 809 (64.4%) | 67 (49.6%) | 237 (48.4%) | 200 (80.3%) | 305 (79.6%) | | | Aspartate aminotransferase (U/L), (%) | | | | | | <0.001 | | ≤18 | 500 (39.8%) | 70 (51.9%) | 256 (52.2%) | 62 (24.9%) | 112 (29.2%) | | | >18 | 757 (60.2%) | 65 (48.1%) | 234 (47.8%) | 187 (75.1%) | 271 (70.8%) | | | Total cholesterol (mmol/L), (%) | | | | | | 0.174 | | ≤ 4.71 | 592 (47.1%) | 67 (49.6%) | 247 (50.4%) | 109 (43.8%) | 169 (44.1%) | | | >4.71 | 665 (52.9%) | 68 (50.4%) | 243 (49.6%) | 140 (56.2%) | 214 (55.9%) | | | High-density lipoprotein cholesterol (mmol/L), (%) | | | | | | <0.001 | | ≥1.36 | 560 (44.6%) | 69 (51.1%) | 249 (50.8%) | 86 (34.5%) | 156 (40.7%) | | | <1.36 | 697 (55.4%) | 66 (48.9%) | 241 (49.2%) | 163 (65.5%) | 227 (59.3%) | | | Triglyceride (mmol/L), (%) | | | | | | <0.001 | | ≤0.9 | 425 (33.8%) | 69 (51.1%) | 249 (50.8%) | 38 (15.3%) | 69 (18.0%) | | | >0.9 | 832 (66.2%) | 66 (48.9%) | 241 (49.2%) | 211 (84.7%) | 314 (82.0%) | | | Low-density lipoprotein cholesterol (mmol/L), (%) | | | | | | 0.031 | | ≤2.65 | 585 (46.5%) | 72 (53.3%) | 244 (49.8%) | 103 (41.4%) | 166 (43.3%) | | | >2.65 | 672 (53.5%) | 63 (46.7%) | 246 (50.2%) | 146 (58.6%) | 217 (56.7%) | | | Glucose (mmol/L), (%) | | | | | | <0.001 | | ≤5.25 | 628 (50.0%) | 83 (61.5%) | 375 (76.5%) | 47 (18.9%) | 123(32.1%) | | | >5.25 | 629 (50.0%) | 52 (38.5%) | 115 (23.5%) | 202 (81.1%) | 260 (67.9%) | | | Glycated hemoglobin (%), (%) | | | | | | <0.001 | | ≤5.5 | 543 (43.2%) | 86 (63.7%) | 273 (55.7%) | 50 (20.1%) | 134 (35.0%) | | | >5.5 | 714 (56.8%) | 49 (36.3%) | 217 (44.3%) | 199 (79.9%) | 249 (65.0%) | | | Fasting insulin (uIU/ml), (%) | | | | | | <0.001 | | ≤3.89 | 915 (72.8%) | 85 (63%) | 429 (87.6%) | 62 (24.9%) | 339 (88.5%) | | | >3.89 | 342 (27.2%) | 50 (37%) | 61 (12.4%) | 187 (75.1%) | 44 (11.5%) | | | Homeostasis model assessment-beta (%), (%) | | | | | | <0.001 | | ≥47.1 | 506 (40.3%) | 119 (88.1%) | 220 (44.9%) | 107 (43.0%) | 60 (15.7%) | | | <47.1 | 751 (59.7%) | 16 (11.9%) | 270 (55.1%) | 142 (57.0%) | 323 (84.3%) | |
|
|
